.webp?width=217&height=60&name=Screenpoint-Med%20(1).webp "Screen Point Medical")
MASAI RCT: 12% reduction in interval cancer rate using Transpara
%20(1).png)
MASAI RCT: 12% reduction in interval cancer rate using Transpara
Transpara® Breast AI Selected for $16M PRISM Randomized Controlled Trial in USA
.png)
Transpara® Breast AI Selected for $16M PRISM Randomized Controlled Trial in USA
ScreenPoint Medical Enables Transpara® Breast AI within Precision Imaging Network, part of Microsoft for Healthcare
.png)
ScreenPoint Medical Enables Transpara® Breast AI within Precision Imaging Network, part of Microsoft for Healthcare
ScreenPoint Medical: AI-Enhanced Mammography Screening Significantly Improves Breast Cancer Detection and Reduces Radiologist Workload
.png)
ScreenPoint Medical: AI-Enhanced Mammography Screening Significantly Improves Breast Cancer Detection and Reduces Radiologist Workload
Only randomized controlled trial of its kind highlights impact of Transpara Breast AI
February 10, 2025
ScreenPoint Medical Acquires Biomediq A/S to Expand Breast Cancer Risk Assessment Capabilities
ScreenPoint Medical Acquires Biomediq A/S to Expand Breast Cancer Risk Assessment Capabilities
Deal brings enhanced capabilities for ScreenPoint’s industry-leading Transpara Breast AI.
January 08, 2025